October 24, 2017 / 10:54 AM / 24 days ago

BRIEF-Zealand Pharma granted orphan drug designation by FDA

Oct 24 (Reuters) - ZEALAND PHARMA A/S:

* REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME

* ‍FDA OFFICE OF ORPHAN PRODUCTS DEVELOPMENT HAS GRANTED AN ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below